{"filing":{"accession_number":"0001213900-26-088719","cik":"0001500198","ticker":"NMTC","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ea0301787-8k_neuroone.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026088719/ea0301787-8k_neuroone.htm"},"events":[{"id":27545,"run_id":25114,"accession_number":"0001213900-26-088719","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses NeuroOne's fiscal Q3 2026 financial results via press release dated August 13, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release reports product revenue of $2.0 million (16% YoY growth), gross margins expanding to 59.9%, and product orders of $2.7 million during the quarter, along with operational highlights including ISO 13485 certification and StereoCED platform development milestones. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and operational progress.","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":29125,"accession_number":"0001213900-26-088719","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses NeuroOne's fiscal Q3 2026 financial results via press release dated August 13, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release reports product revenue of $2.0 million (16% YoY growth), gross margins expanding to 59.9%, and product orders of $2.7 million during the quarter, along with operational highlights including ISO 13485 certification and StereoCED platform development milestones. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:16:51.000177+00:00","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","filing_date":"2026-08-13"}]}